Recent Finacing
Recent Raise
OnKure is a clinical-stage biopharmaceutical company using structure-based drug design to discover and develop tumor-agnostic, epigenetics-driven small-molecule cancer therapies, including selective Class I HDAC and PI3K alpha H1047R inhibitors.
